The Treatment of Older Patients With Multiple Myeloma
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma.
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma. This interview took place at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
-Every year in the U.S., 10,000 people under the age of 70 and 10,000 people over the age of 70 are diagnosed with multiple myeloma
-Younger patients typically experience better outcomes while older patients do not see much improvement
@TargetedOncUsing newer therapy strategies, my projection is that#MultipleMyelomapts 70+ yrs will have 2-3x better survival within 5 yrs
Ola Landgren, M.D. (@DrOlaLandgren)April 9, 2014
-Now that older patients are being treated with new drugs, they​ are seeing an improvement in survival
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
